Published in Medical Letter on the CDC and FDA, November 22nd, 2009
"The expanded indication gives physicians the option to prescribe BYETTA as a first-line treatment, increasing the number of patients who may...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.